BERLIN & NEVADA--(BUSINESS WIRE)--MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the installation of the fourth NanoActivator(R). The device was installed at Cologne University Hospital to provide NanoTherm(TM) therapy for the treatment of brain cancers and Cologne University Hospital will participate in MagForce's post marketing study. Since NanoTherm(TM) therapy has the European CE mark (in the 27 EU countries), commercial patients can also be treated in Cologne. NanoActivator(R) devices are now available for treatment of patients at the University Medical Centers in Cologne, Kiel, Münster and Berlin.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
